Key statistics
On Friday, Neurocrine Biosciences Inc (NB3:STU) closed at 105.05, 6.30% above its 52-week low of 98.82, set on Nov 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 107.10 |
---|---|
High | 107.10 |
Low | 105.05 |
Bid | 105.30 |
Offer | 106.75 |
Previous close | 107.05 |
Average volume | 0.00 |
---|---|
Shares outstanding | 100.98m |
Free float | 99.33m |
P/E (TTM) | 35.74 |
Market cap | 11.95bn USD |
EPS (TTM) | 3.31 USD |
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Press releases
- Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
- Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
- Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
- Neurocrine Biosciences to Participate at Investor Conferences in September
- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
- Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
- Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
- Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
- Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
- Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
More ▼